.Pharmacolibrary.Drugs.ATC.L.L01EH02 .Pharmacolibrary.Drugs.ATC.L.L01EH02| name: | Neratinib | |
| ATC code: | L01EH02 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 240 | mg |
| volume of distribution: | 2360 | L |
| clearance: | 216 | L/h |
| other parameters in model implementation | ||
Neratinib is an oral, irreversible tyrosine kinase inhibitor targeting HER2 and EGFR receptors. It is primarily used for the extended adjuvant treatment of early-stage HER2-positive breast cancer and is an FDA-approved medication.
Population pharmacokinetics in cancer patients (mainly women, adults) after oral administration; parameters represent typical values from published clinical pharmacology studies.